PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Condition(s):MSI-H; PD-1 Immunotherapy; Gastric Cancer; Adjuvant TherapyLast Updated:August 26, 2022Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):MSI-H; PD-1 Immunotherapy; Gastric Cancer; Adjuvant TherapyLast Updated:August 26, 2022Not yet recruiting
Condition(s):Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction CarcinomaLast Updated:February 12, 2024Not yet recruiting
Condition(s):Gastric Cancer; Lung CancerLast Updated:February 6, 2018Completed
Condition(s):Metastatic Gastric CancerLast Updated:December 9, 2020Unknown status
Condition(s):Esophageal Neoplasms; Lymph Node MetastasesLast Updated:February 13, 2024Recruiting
Condition(s):Gastroesophageal Junction (GEJ) AdenocarcinomaLast Updated:July 28, 2023Recruiting
Condition(s):Gastric Cancer; Microsatellite InstabilityLast Updated:October 31, 2023Recruiting
Condition(s):Esophageal Adenocarcinomas; Adenocarcinomas of the Gastroesophageal JunctionLast Updated:November 25, 2013Terminated
Condition(s):Adenocarcinoma of the Gastroesophageal Junction; Esophageal CancerLast Updated:November 29, 2012Completed
Condition(s):Siewert Type II Adenocarcinoma of Esophagogastric JunctionLast Updated:June 8, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.